Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Moderate-to-Severe COPD With Type 2 Inflammation (China Substudy of Phase III)
CTR20191944Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of dupilumab in chronic obstructive pulmonary disease (COPD), sponsored by Sanofi. Started Oct 2019; status: completed.
02
Drugs
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20191944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191944.